

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Improved strategy for identifying individuals with hereditary diffuse gastric cancer

Benjamin Lerner, MD

Fellow of Medicine, Department of Internal Medicine (Digestive Diseases)
Yale School of Medicine

Tuesday, May 31, 2022
5:00 - 6:00 pm

<https://zoom.us/j/99162012581?pwd=Rlk1VXN1UmxEems1S2s1bGVJZUJwdz09>

Host: Xavier Llor, MD, PhD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29450) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Hereditary diffuse gastric cancer (HDGC) is an autosomal-dominant syndrome characterized by early-onset diffuse gastric cancer (DGC), as well as lobular breast cancer. Pathogenic germline variants in the *CDH1* gene have been identified as a major cause of this syndrome. DGC has a poor prognosis, largely because patients often present with vague symptoms, leading to delays in diagnosis. Identification of *CDH1* mutation carriers is important because DGC may be prevented by prophylactic total gastrectomy or detected early by endoscopic surveillance. **Objectives:** Review the generally accepted guidelines for genetic testing and management of HDGC written by the International Gastric Cancer Linkage Consortium (IGCLC); Discuss the limitations of the IGCLC's clinical criteria for genetic testing; Propose simpler and more sensitive criteria for identifying individuals with pathogenic *CDH1* variants. **Faculty Disclosures:** Faculty for this educational activity have no relevant financial relationship with ineligible companies to disclose. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**